Xencor Inc XNCR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
2.23
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $125.6M | -$91.9M | — | -$138.3M | $635.6M |
| 2024 | $110.5M | -$232.6M | — | -$208.3M | $674.0M |
| 2023 | $174.6M | -$133.1M | — | -$96.4M | $662.1M |
| 2022 | $164.6M | -$55.2M | — | -$14.0M | $727.5M |
| 2021 | $275.1M | $82.6M | — | -$30.2M | $733.5M |
| 2020 | $122.7M | -$69.3M | — | -$15.5M | $572.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Feigal Ellen | director | 2026-06-18 | Sell | 6,843 | $13.06 |
| GORMAN KEVIN CHARLES | director | 2026-06-15 | Sell | 7,527 | $12.31 |
| GUSTAFSON KURT A | director | 2026-06-15 | Sell | 5,474 | $12.31 |
| RANIERI RICHARD J | director | 2026-06-15 | Sell | 5,474 | $12.31 |
| Montgomery Alan Bruce | director | 2026-06-15 | Sell | 5,064 | $12.31 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | 2026-04-10 | Sell | 3,499 | $12.29 |
| Dahiyat Bassil I | PRESIDENT & CEO | 2026-03-06 | Sell | 6,606 | $11.02 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO | 2026-03-06 | Sell | 2,502 | $11.02 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.23 (grey)
- Working capital / assets 0.576
- Retained earnings / assets -0.909
- EBIT / assets -0.203
- Equity / liabilities 2.649
Source: SEC EDGAR filings · CIK 0001326732 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.